Korean Society of Circulation 50th Annual Scientific Meeting

Seoul, Korea – October 12, 2006

Basic Research Session on

Translational Cardiovascular Research

"Cell and Molecular Therapies for Cardiac Repair"

Origins of cell therapy in congestive heart failure:

- Several groups have had a long-standing interest in the use of donor cells to promote angiogenesis with the notion that this could provide revascularization therapy in ischemic myocardium
- In the 1990s, several groups demonstrated that skeletal myoblasts form stable grafts in hearts; some suggested that the donor cells adopted a "cardiac phenotype"
- Studies in the late 1990s / early 2000s suggested that adult stem cells have a greater capacity for cross-lineage differentiation then previously thought (i.e., "trans-differentiation" from blood to brain, blood to muscle, etc)
- Many preclinical cell transplantation studies indicated that donor cell transplantation improved cardiac function in injured hearts
- Clinical studies with cell transplantation have yielded variable results; the impact on cardiac function observed to date has been somewhat disappointing (particularly given some of the pre-clinical results)

• There are several ways that donor cells can help injured hearts (i.e., vasculogenesis, anti-apoptosis, direct cardiomyogenesis)

- True <u>regeneration</u> of damaged hearts requires the formation of new cardiomyocytes (CMs) this is the main interest of my laboratory
- Tracking the cardiomyogenic fate & utility of donor cells requires the availability of good markers (either intrinsic or genetic tags) <u>and</u> the ability to demonstrate functional competence at the cellular level, respectively
- Today's presentation will demonstrate:

- that fetal CMs form stable and functionally integrated grafts (we use transgenic reporter mice to demonstrate these traits)

- that skeletal myoblasts, marrow-derived HSCs, mono-nuclear cells, and Sca-1⁺ cardiac resident cells engraft, but for the most part do not form integrated myocytes (except perhaps via rare cell fusion events)

- that human ES-derived CMs form stable grafts

Tracking differentiation of donor fetal CMs:



Adult heart section (X-GAL stained)

- Isolate E15.5 txg hearts
- Digest with collagenase
- Tsp. CMs into non-txg recipient
- Harvest heart, stain with X-GAL; blue nuclei indicate that donor cells underwent CM differentiation



Vibratome Section



Thin Section

Tracking survival & function of donor fetal CMs:



Adult heart section (epifluorescence)

- Isolate E15.5 txg hearts
- Digest with collagenase
- Tsp. CMs into non-txg recipient
- Visualize via epi-fluorescence; green signal indicates donor cell survival



Vibratome Section



Thin Section

Image analysis for donor cell function

- Harvest heart with EGFP donor cell graft
- Langendorff-perfuse with cytochalasin D (uncouples excitation/contraction) and Rhod-2 (increases fluorescence with [Ca²⁺]_i)
- Image Rhod-2 and EGFP fluorescence via two photon laser scanning microscopy





- Harvest heart with EGFP donor cell graft
- Langendorff-perfuse with cytochalasin D (uncouples excitation/contraction) and Rhod-2 (increases fluorescence with [Ca²⁺]_i)
- Image Rhod-2 and EGFP fluorescence via two photon laser scanning microscopy





Simultaneous recording of intracellular calcium transients in neighboring donor and host CMs:



All donor CMs transplanted into normal ventricle were observed to be coupled (>400 analyzed; distributed between >18 recipient mice)

Tracking survival & function of donor SMBs:



- Isolate and amplify skeletal myoblasts
- Transplant EGFP donor cells into the hearts of non-transgenic mice



• Image for Rhod-2 and EGFP fluorescence

Simultaneous recording of intracellular calcium transients in neighboring host CMS and SMB-derived myocytes:



The <u>vast</u> majority of donor-derived myocytes do not couple with the host myocardium following skeletal MB transplantation (>99.9%); a few cells at the graft / myocardium border appeared to be coupled, but subsequent analyses indicated that these likely arose from CM-SMB fusion events

Tracking differentiation of donor HSCs:



• Prepare BM-derived HSCs



- Transplant into infarcted hearts
- Harvest heart, vibratome section and stain with X-GAL

Absence of X-GAL reaction product suggests donor cells do not differentiate into CMs



Tracking survival & function of donor HSC:



• Prepare BM-derived HSCs



Transplant into infarcted hearts

Donor HSC-derived cells readily identified based on EGFP epi-fluorescence



Image for donor cell function

Simultaneous recording of intracellular calcium transients in neighboring host CMs and donor HSC-derived cells:



No $[Ca^{2+}]_i$ transients were observed in HSC-derived cells at 9 days posttransplantation with either point or field stimulation (>20 mice, 800 cells analyzed); similar results with crude marrow mononuclear preparations

Tracking differentiation & function of donor Sca-1⁺ cells:

Actin-EGFP / MHC-nLAC double txg mice Ubiquitous EGFP, blue CM nuclei

- Mince adult hearts and disperse cells
- Gate on EGFP positive, Sca-1 positive, lineage negative cells
- Transplant into infarcted hearts
- Harvest heart,

X-GAL stain,

visualize



No MHC-nLAC transgene expression (X-GAL stained vibratome section)



Donor HSCs readily identified via EGFP epifluorescence



Records of intracellular calcium transients in host CMs and donor Sca-1⁺-derived cells (field stimulation):



No [Ca²⁺]_i transients were observed in Sca-1⁺-derived cells between 9 and 21 days post-transplantation (5 mice, 370 cells imaged), however...

...some EGFP⁺ cells exhibited a "CM-like" morphology:

EGFP epi-fluorescence

Anti- α -actinin IgG (rhodamine)



The appearance of such cells is very rare (only 3 of ca. 5,000 EGFP⁺ cells screened); absence of X-GAL signal suggests either a failure in terminal differentiation or fusion with subsequent nuclear reprogramming ...

Preliminary experiments with human ES-derived CMs:

Our goal was to see if CMs generated at a remote site could be shipped and successfully engrafted into normal or injured myocardium



"Shipped" hEBs have spontaneous contractile activity:

Spontaneous [Ca²⁺]_I transients (A) and integrated trace (B) in hEBs



Anti-EGFP IgG Non-specific IgG





Anti-MHC IgG

EGFP epi-fluor.



Shipped hES-derived CMs form stable grafts in vivo:

Anti-GFP IgG (HRP secondary)



Non-specific IgG (HRP secondary)



EGFP epifluorescence



Rhodamine channel Epifluorescence



CM differentiation at 4 weeks post-transplantation:







- 6 of 6 non-infarcted hearts had hES cells
- IgG analyses of infarcted hearts is in progress; there appears to be poorer CM survival when injected into scar
- Bob Kloner's data suggest modest functional improvement (direct vs. indirect effect?)

Summary / take home messages:

- Fetal CMs form stable grafts and functionally integrate with the host myocardium
- Skeletal myoblasts form stable grafts but are not electromechanically coupled to the host myocardium; rare fusion events give rise to myocytes with heterogeneous [Ca²⁺]₁ (source of clinical arrhythmias?)
- Lin⁻ / cKit⁺ BMSCs or marrow-derived mononuclear cells form stable grafts but to not form CMs; any clinical benefit from these cells is not due to their ability to directly form new muscle
- Cardiac resident Sca-1+ cells form stable grafts, but the majority of cells do not form cardiomyocytes and are not electromechanically coupled; studies are underway to determine if the few CM-like cells observed arise from fusion events or from cardiomyogenic differentiation
- Human ES-derived CMs can form stable grafts following transplantation into normal and infarcted hearts; preliminary coupling analyses look promising

SCIENTISTS (for the unpublished studies only):

MI + Cell tsp & analyses:

Mark Soonpaa, Ph.D.,

Pascal LaFontant, Ph.D.

TPME imaging & analyses:

Michael Rubart, M.D. (PEDS, IUSM)

John Scherschel, M.D.

Adult heart stem cell isolation:

Ed Srour, Ph.D. (MED, IUSM)

Human ES cell experiments:

Bob Kloner M.D. (GSH, Los Angeles) Robert Zweigerdt Ph.D. (ESI)

2007 Weinstein Cardiovascular Development Conference

Indianapolis, Indiana



Union Station Crowne Plaza Hotel May 10th – 12th 2007

Keynote speakers: Drs. Oliver Smithies and Peggy Kirby

http://www.weinsteinmeeting.org

& stay an extra night to see 'Indy 500 time-trials'